ZIVO Bioscience Income After Taxes 2016-2024 | ZIVO

ZIVO Bioscience income after taxes from 2016 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.

ZIVO Bioscience Income After Taxes 2016-2024 | ZIVO

ZIVO Bioscience income after taxes from 2016 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$168.1B
Vertex Pharmaceuticals (VRTX)$119.2B
Regeneron Pharmaceuticals (REGN)$113.7B
Gilead Sciences (GILD)$102.4B
Bristol Myers Squibb (BMY)$101.3B
CSL (CSLLY)$95.4B
GSK (GSK)$84.1B
Alnylam Pharmaceuticals (ALNY)$35B
Argenex SE (ARGX)$32.8B
Biogen (BIIB)$27.5B
BioNTech SE (BNTX)$27.5B
Moderna (MRNA)$24.5B
BeiGene (BGNE)$20.1B
Illumina (ILMN)$20.1B
Genmab (GMAB)$15.8B
BioMarin Pharmaceutical (BMRN)$13.1B
Vaxcyte (PCVX)$12.7B
Exact Sciences (EXAS)$12.5B
Insmed (INSM)$12.5B
Incyte (INCY)$12.2B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.1B
Bio-Rad Laboratories (BIO.B)$9.1B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$8.5B
Legend Biotech (LEGN)$7.9B
Intra-Cellular Therapies (ITCI)$7.9B
Repligen (RGEN)$7.8B
Exelixis (EXEL)$7.4B